Greenwood Capital Associates LLC Purchases 21,240 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Greenwood Capital Associates LLC lifted its position in OptimizeRx Co. (NASDAQ:OPRX) by 31.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 88,596 shares of the company’s stock after buying an additional 21,240 shares during the period. Greenwood Capital Associates LLC owned about 0.48% of OptimizeRx worth $431,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in OPRX. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the last quarter. Quest Partners LLC increased its holdings in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares in the last quarter. SG Americas Securities LLC purchased a new position in OptimizeRx in the 4th quarter worth about $51,000. Barclays PLC lifted its stake in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after acquiring an additional 21,060 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of OptimizeRx during the 2nd quarter valued at about $282,000. Institutional investors own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. JMP Securities lowered their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. William Blair restated an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus dropped their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.06.

OptimizeRx Stock Up 1.0 %

OptimizeRx stock opened at $5.79 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. OptimizeRx Co. has a 12-month low of $3.78 and a 12-month high of $16.65. The firm has a 50 day moving average of $5.23 and a 200 day moving average of $6.60.

Insider Activity

In other OptimizeRx news, CEO William J. Febbo purchased 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 6.10% of the company’s stock.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.